This site is intended for healthcare professionals
COMT inhibition in Parkinson’s Disease

Disease progression

Read time: 15 mins

PD progression is characterised by a worsening of motor and non-motor features, which can no longer be managed with symptomatic therapies1. Levodopa-induced motor complications are common due to increased disease severity and higher drug doses which cause a narrowing of the levodopa therapeutic window2.  

As PD advances complications related to long-term symptomatic treatment emerge, these include non-motor and motor fluctuations (Figure 1) as well as dyskinesia and psychosis1

Register free for full access to

Developed by EPG Health for Medthority in collaboration with BIAL, with content provided by BIAL. Job code: ON/FEV20/G/183.